Health TrialsbyHealthPanel

Strategy for EArly Recognition of Cancer, COPD & Heart Failure in the Emergency Department

ConditionsCancerCardiovascularRespiratory
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorNHS Greater Glasgow and Clyde

About this trial

SEARCH-ED is a research study which is running in Emergency Department (ED) of the Queen Elizabeth University Hospital. The aim of the study is to find out if using a computer programme can help doctors diagnose heart and lung problems from chest x-rays.

We want to compare how many people are diagnosed with heart or lung problems for the first time when doctors have access to the computer programme results, in comparison to when they don't.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Frontal Chest X-Ray (CXR) (AP or PA) acquired in the Queen Elizabeth University Hospital (QEUH) ED

Patients aged 18 or over

Appropriate meta data (DICOM) to allow for Harrison CXR processing and secondary capture report provision.

Aged 18 or over

Disqualifiers

Patients not available to follow up, including patients i.e. whose the patient's usual care (or onward care following index admission) is out-with NHS GGC.

Patients who have been referred to palliative care for end-stage disease, or patients with severe frailty (i.e. bedbound) will not be invited to the combined diagnostic clinic

Unable to provide informed written consent in English

Aged <18

Trial design

Design model

Parallel

Treatments tested in this trial

  • Harrison.ai Chest X-Ray Solution

    Device

    The Harrison.ai CXR module is an AI-driven clinical decision support tool that is designed to augment clinical interpretation of CXRs. It is a Class IIb CE-marked device which is able to detect up to 124 findings on a CXR.

Treatment groups

17,000 Participants
are divided into 2 treatment groups
Group A: Harrison CXR 'ON' BlockExperimental treatment 1 intervention
Group B: Harrison CXR 'OFF' BlockActive comparator 1 intervention

Trial outcomes

Primary outcomes

1

Proportion of patients identified with a confirmed new diagnosis of heart failure, based on subsequent clinical assessment and guideline-based investigation.

Time frame
12 months

Secondary outcomes

1

Duration of admission during index hospitalisation

Time frame
12 months
2

Time to initiation of guideline-based, long-term therapy for Chronic obstructive pulmonary disease (COPD) and Heart Failure.

For Chronic obstructive pulmonary disease (COPD), this will be defined as first prescription of combined long acting beta agonist (LABA)/long acting muscarinic antagonist (LAMA) inhaler or LABA/LAMA/inhaled corticosteroid (single or split) inhaler therapy. For Heart Failure , this will be defined as first prescription of either a) a renin-angiotensin system inhibitors, b) a beta blocker, or c) an SLGT2 inhibitor.

Time frame
12 months
3

Time to diagnostic testing for Heart Failure, COPD and lung cancer (echocardiography, spirometry, CT).

Time frame
12 months
4

Time to inpatient or outpatient specialist review and confirmation of lung cancer, COPD or Heart Failure

Time frame
12 months

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

NHS Greater Glasgow and Clyde

Lead sponsor

University of Glasgow

Collaborator

Source ClinicalTrials.gov
Apply now